Literature DB >> 18854983

Combined effect of protein kinase B inhibitor or extracellular signal-regulated kinase inhibitor against farnesyltransferase inhibition-induced apoptosis in SiHa cells.

Sun Joo Lee1, Chung Soo Lee.   

Abstract

The present study investigated the combined effect of Akt or extracellular signal-regulated kinase (ERK) inhibition in the presence of farnesyltransferase inhibitor against human cervix and uterus tumor cell line SiHa cells. Farnesyltransferase inhibitor may induce apoptosis through the mitochondria-mediated process and inhibition of the MEK, ERK, and Akt activity. Inhibitors of Akt and ERK at low concentrations seem to prevent the farnesyltransferase inhibitor-induced apoptosis in cervical SiHa cells by suppressing the mitochondrial membrane permeability change that leads to cytochrome c release and caspase-3 activation. These effects may be associated with inhibition of the reactive oxygen species formation and glutathione depletion. In contrast, at higher concentrations more than 1 microM, the Akt inhibitor and ERK inhibitor seem to exhibit an additive toxic effect against farnesyltransferase inhibitor-induced apoptosis by increasing mitochondrial membrane permeability change and oxidative stress, which may not involve inhibition of MEK, ERK, and Akt activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18854983     DOI: 10.1007/s00210-008-0359-7

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  45 in total

Review 1.  Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review).

Authors:  Fumin Chang; Linda S Steelman; John G Shelton; John T Lee; Patrick M Navolanic; William L Blalock; Richard Franklin; James A McCubrey
Journal:  Int J Oncol       Date:  2003-03       Impact factor: 5.650

Review 2.  Review: The role of glutathione in the regulation of apoptosis.

Authors:  A G Hall
Journal:  Eur J Clin Invest       Date:  1999-03       Impact factor: 4.686

3.  Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress.

Authors:  Jane E Cavanaugh; Juliann D Jaumotte; Joan M Lakoski; Michael J Zigmond
Journal:  J Neurosci Res       Date:  2006-11-01       Impact factor: 4.164

Review 4.  The ras signalling pathway as a target in cancer therapy.

Authors:  Kathryn Graham; Michael F Olson
Journal:  Recent Results Cancer Res       Date:  2007

Review 5.  Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival.

Authors:  Steven Grant; Liang Qiao; Paul Dent
Journal:  Front Biosci       Date:  2002-02-01

6.  Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis.

Authors:  Roy Blum; Jasmine Jacob-Hirsch; Gideon Rechavi; Yoel Kloog
Journal:  Mol Cancer Ther       Date:  2006-09       Impact factor: 6.261

7.  Increase in gamma-glutamyltransferase by glutathione depletion in rat type II pneumocytes.

Authors:  R J van Klaveren; P H Hoet; J L Pype; M Demedts; B Nemery
Journal:  Free Radic Biol Med       Date:  1997       Impact factor: 7.376

8.  Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells.

Authors:  M E Beiner; H Niv; R Haklai; G Elad-Sfadia; Y Kloog; G Ben-Baruch
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

9.  The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro.

Authors:  Robert A McPherson; Mark C Conaway; Chris W Gregory; Wei Yue; Richard J Santen
Journal:  Prostate       Date:  2004-03-01       Impact factor: 4.104

10.  Ras inhibition amplifies cisplatin sensitivity of human glioblastoma.

Authors:  Samantha Messina; Carlo Leonetti; Giorgia De Gregorio; Valentina Affatigato; Giuseppe Ragona; Luigi Frati; Gabriella Zupi; Angela Santoni; Antonio Porcellini
Journal:  Biochem Biophys Res Commun       Date:  2004-07-23       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.